Bioactive natural products in COVID-19 therapy

Wang, Zhonglei; Wang, Ning; Yang, Liyan; Song, Xian-qing

doi:10.3389/fphar.2022.926507

Cited by 44 publications

(31 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sanghuangporus sanghuang can significantly decrease the expression of ACE2 and transmembrane protease serine 2 and reduce their expression in mouse liver and kidney tissues ( 183 ). In addition, many natural products (gallinamide A, cordycepin, telocinobufagin, plitidepsin, and tylophorine) are able to target the SARS-CoV-2 main protease (Mpro), RNA-dependent RNA polymerase, papain-like protease, and spike glycoprotein, manifesting potential functions in the treatment of COVID-19 ( 184 ). However, the efficacy and safety of these Chinese medicine preparations and natural products need to be further evaluated.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundSince the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.MethodsPublications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.Results1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. CLINICAL INFECTIOUS DISEASES and FRONTIERS IN IMMUNOLOGY were the most essential immunology journals. These immunology journals mostly focused on the following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, and “long COVID”.ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fast-spreading SARS‐CoV‐2 variants cause resurgence of infections raise several concerns ( 113 ). However, VV116 was found to retain its anti-viral capacity against the Alpha, Beta, Gamma, Delta, as well as Omicron (EC 90 = 0.30 μM) variants of SARS-CoV-2 ( 114 ).…”

Section: The Orally Administered Versions Of Gs-441524mentioning

confidence: 99%

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Wang

Yang

Song³

2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral bioavailability of GS‐441524 poses a challenge to its anti-SARS-CoV-2 efficacy. Remdesivir, the intravenously administered version (version 1.0) of GS-441524, is the first FDA-approved agent for SARS-CoV-2 treatment. However, clinical trials have presented conflicting evidence on the value of remdesivir in COVID-19. Therefore, oral GS-441524 derivatives (VV116, ATV006, and GS-621763; version 2.0, targeting highly conserved viral RdRp) could be considered as game-changers in treating COVID-19 because oral administration has the potential to maximize clinical benefits, including decreased duration of COVID-19 and reduced post-acute sequelae of SARS-CoV-2 infection, as well as limited side effects such as hepatic accumulation. This review summarizes the current research related to the oral derivatives of GS-441524, and provides important insights into the potential factors underlying the controversial observations regarding the clinical efficacy of remdesivir; overall, it offers an effective launching pad for developing an oral version of GS-441524.

show abstract

“…For some compounds, particularly pharmaceutical drugs, toxicity data was accessible from public documents for their approval by either the FDA or the European Medicines Agency. Many of the natural products included have long histories of use in food as well as herbal medicines ( Wang and Yang, 2020 , 2021 ; Yang and Wang, 2021 ; Wang et al, 2022 ). Many are found in common foods and show strong association with positive health outcomes ( Kumar and Pandey, 2013 ), including possible antiviral and antineoplastic ( Rodriguez-García et al, 2019 ) properties.…”

Section: Main Considerationsmentioning

confidence: 99%

Therapeutic potential of compounds targeting SARS-CoV-2 helicase

et al. 2022

View full text Add to dashboard Cite

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.

show abstract

Bioactive natural products in COVID-19 therapy

Cited by 44 publications

References 123 publications

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Therapeutic potential of compounds targeting SARS-CoV-2 helicase

Contact Info

Product

Resources

About